To fight COVID 19 the pharmaceutical company Eli Lilly and

Last updated: 2/24/2023

To fight COVID 19 the pharmaceutical company Eli Lilly and Co designed and developed a treatment of a monoclonal antibody bamlanivimab that recognizes the spike protein found on the surface of the novel coronavirus The spike protein is required for entry into human cells so the antibody protein binding to it blocks the ability of the virus to infect our cells On Nov 9 2020 the US FDA granted an emergency use authorization for the antibody to be used to fight severe COVID 19 infections By April 2021 the FDA revoked its authorization because the coronavirus had mutated and the antibody was no longer effective at inhibiting the new variants from infecting our cells Based on the finding that new variants of coronavirus are no longer inhibited by the monoclonal antibody bamlanivimab which of the following statements is true about the interaction between bamlanivimab and the mutated coronavirus spike protein O The number of noncovalent bonds between antibody and mutant spike protein increased The number of noncovalent bonds between antibody and mutant spike protein decreased The number of covalent bonds between antibody and mutant spike protein increased The number of covalent bonds between antibody and mutant spike protein decreased O